OAC
IBRX icon

OMERS Administration Corp’s ImmunityBio IBRX Stock Holding History

OMERS Administration Corp’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-70,300
Closed -$444K – 979
2024
Q2 		$444K Buy
+70,300
New +$464K ﹤0.01% 697
2017
Q1 		– Sell
-13,900
Closed -$80K – 361
2016
Q4 		$80K Buy
+13,900
New +$92.7K ﹤0.01% 308

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

OMERS Administration Corp's IBRX Position: Q3 2024 in Review

OMERS Administration Corp sold out of ImmunityBio (IBRX) in Q3 2024, closing a stake of 70,300 shares — an estimated $444K sold.

OMERS Administration Corp first reported a position in IBRX in Q4 2016 and held it in 2 quarters. The position peaked at $444K in Q2 2024. 181 funds tracked by Wall St. Rank hold IBRX as of Q3 2024.

  • OMERS Administration Corp reported no remaining ImmunityBio position as of Q3 2024 after selling out during the quarter.
  • OMERS Administration Corp sold 70,300 ImmunityBio shares in Q3 2024, an estimated $444K.
  • OMERS Administration Corp first reported a position in ImmunityBio in Q4 2016 and held it in 2 quarters.
  • OMERS Administration Corp's ImmunityBio position peaked at $444K in Q2 2024.
  • 181 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2024.

Based on OMERS Administration Corp's 13F filing for Q3 2024, filed 13 Nov 2024.